Compare · MRNA vs TARA
MRNA vs TARA
Side-by-side comparison of Moderna Inc. (MRNA) and Protara Therapeutics Inc. (TARA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MRNA and TARA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $23.55B, about 101.9x TARA ($231.0M).
- MRNA has been more active in the news (14 items in the past 4 weeks vs 10 for TARA).
- MRNA has more recent analyst coverage (25 ratings vs 6 for TARA).
- Company
- Moderna Inc.
- Protara Therapeutics Inc.
- Price
- $59.35-7.16%
- $4.11+3.40%
- Market cap
- $23.55B
- $231.0M
- 1M return
- +23.34%
- -
- 1Y return
- +131.02%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2014
- News (4w)
- 14
- 10
- Recent ratings
- 25
- 6
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Protara Therapeutics Inc.
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
Latest MRNA
- Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine
- SEC Form 144 filed by Moderna Inc.
- President Hoge Stephen sold $2,739,870 worth of shares (53,336 units at $51.37) as part of a pre-agreed trading plan and exercised 53,336 shares at a strike of $19.15 (SEC Form 4)
- Moderna to Host Investor Event - Science Day
- Moderna Announces Organizational Changes to Prepare for Multiple Product Launches in 2027 and 2028
- Moderna and the University of Oxford Receive UK Authorization to Begin Phase 1/2 Study of Investigational mRNA Cancer Vaccine for People with Lynch Syndrome
- Chief Legal Officer Klinger Shannon Thyme exercised 15,269 shares at a strike of $7.04, sold $173,550 worth of shares (3,471 units at $50.00) as part of a pre-agreed trading plan and covered exercise/tax liability with 5,705 shares, increasing direct ownership by 9% to 73,561 units (SEC Form 4) to cover withholding tax
- Chief Financial Officer Mock James M converted options into 11,798 shares and covered exercise/tax liability with 5,705 shares, increasing direct ownership by 10% to 65,687 units (SEC Form 4) to satisfy tax liability
- Chief Financial Officer Mock James M converted options into 2,475 shares and covered exercise/tax liability with 1,197 shares, increasing direct ownership by 2% to 59,594 units (SEC Form 4) to satisfy tax liability
- Chief Legal Officer Klinger Shannon Thyme converted options into 2,165 shares and covered exercise/tax liability with 1,047 shares, increasing direct ownership by 2% to 67,468 units (SEC Form 4) (tax withholding)
Latest TARA
- SEC Form 4 filed by Director Levy Richard S
- SEC Form 4 filed by Director Solomon Michael Edward
- SEC Form 4 filed by Director Smith Cynthia
- SEC Form 4 filed by Director Sargen Gregory
- SEC Form 4 filed by Director Huang Jane
- SEC Form 4 filed by Director Flannelly Barry P
- SEC Form 4 filed by Director Garceau Roger
- SEC Form 4 filed by Director Beshar Luke M
- Protara Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Chief Commercial Officer Conkling William covered exercise/tax liability with 6,008 shares, decreasing direct ownership by 8% to 69,992 units (SEC Form 4) to satisfy withholding tax